Join to View Full Profile
1800 Orleans StreetBaltimore, MD 21287
Phone+1 410-955-5000
Fax+1 410-955-5001
Dr. Oshima is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Kiyoko Oshima is a pathologist in Baltimore, MD. She received her medical degree from Jikei University School of Medicine in Tokyo and has been in practice 39 years. She is the Director of clinical hepatobiliary pathology at Johns Hopkins University. She has more than 60 publications.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pathology-Anatomic and Clinical, 2001 - 2002
University of ChicagoFellowship, Blood Banking/Transfusion Medicine, 2000 - 2001
University of Illinois College of Medicine at ChicagoResidency, Pathology-Anatomic and Clinical, 1996 - 2000
Jikei University School of MedicineClass of 1983
Certifications & Licensure
DC State Medical License 2017 - 2027
CA State Medical License 2001 - 2025
MD State Medical License 2017 - 2025
WI State Medical License 2012 - 2017
IL State Medical License 1996 - 2014
AZ State Medical License 2006 - 2013
MO State Medical License 2008 - 2013
American Board of Pathology Anatomic Pathology- American Board of Pathology Anatomic Pathology & Clinical Pathology
- Join now to see all
Publications & Presentations
PubMed
- Cholangioblastic Cholangiocarcinoma ( NIPBL :: NACC1 Cholangiocarcinoma) : Expanded Morphologic Spectrum and Further Genetic Characterization.Pedram Argani, Kiyoko Oshima, Robert A Anders, Raul S Gonzalez, Osman Yilmaz
The American Journal of Surgical Pathology. 2025-04-01 - 1 citationsTumor-derived CCL2 drives tumor growth and immunosuppression in IDH1- mutant cholangiocarcinoma.Daniel J Zabransky, Emma Kartalia, Jae W Lee, James M Leatherman, Soren Charmsaz
Hepatology. 2024-12-03 - 2 citationsImpact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC.Mari Nakazawa, Mike Fang, Tyrus Vong, Jane Zorzi, Paige Griffith
Cancer Research Communications. 2024-08-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
